<DOC>
	<DOCNO>NCT01765790</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics , pharmacodynamics anti-MIF antibody subject malignant solid tumor ( Arm 1 ) subject metastatic adenocarcinoma colon rectum ( Arm 2 ) .</brief_summary>
	<brief_title>Phase 1 Study Anti-Macrophage Migration Inhibitory Factor ( Anti-MIF ) Antibody Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Main Males females 18 year age old time screen Anticipated life expectancy &gt; 3 month time screen Arm 1 : Histologically confirm malignant solid tumor refractory fail standard treatment , participant consider medically suitable receive standard care treatment refuse standard care treatment Arm 2 : Histologically cytologically confirm diagnosis metastatic adenocarcinoma colon rectum refractory fail standard treatment , participant consider medically suitable receive standard care treatment refuse standard care treatment Measurable evaluable disease ( define study protocol ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Adequate hematological function ( define study protocol ) Adequate renal function ( define study protocol ) Adequate liver function ( define study protocol ) Adequate venous access Arm 2 : At least 1 tumor amenable biopsy , determine investigator , participant must willing undergo biopsy prior least following antimacrophage migration inhibitory factor ( antiMIF ) antibody treatment For woman childbearing potential , participant must negative pregnancy test screening must agree employ 2 form adequate contraceptive measure For male , participant must agree use adequate contraceptive measure include least 1 barrier method , abstain sperm donation throughout course study least 90 day last administration investigational product . Participant willing able comply requirement protocol Main Known brain tumor Central nervous system ( CNS ) metastases Myocardial infarction within 6 month antiMIF antibody administration , congestive heart failure ( New York Heart Association Class III Class IV ) , unstable angina , unstable cardiac arrhythmia require medication , risk factor polymorphic ventricular tachycardia Uncontrolled hypertension Left ventricular ejection fraction ( LVEF ) &lt; 40 % , determine screen echocardiogram ( echocardiogram result obtain within 90 day prior screen acceptable ) QT/QTc interval &gt; 450 msec , determine screen electrocardiogram ( ECG ) Antitumor therapy ( chemotherapy , radiotherapy , antibody therapy , molecular target therapy , retinoid therapy , hormonal therapy ) within 4 week prior administration investigational product ( IP ) ( 6 week nitrosoureas mitomycin C ) . Any previous treatmentrelated toxicity must recover Grade â‰¤ 1 ( grade accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) v4.03 ) . Prior concurrent use hormone deprivation therapy hormonerefractory prostate cancer breast cancer permit . Major surgery within 4 week prior IP administration Active joint inflammation history inflammatory arthritis immune disorder involve joint Active infection require IV antibiotic within 2 week prior screen Known history hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , active tuberculosis . Known history human immunodeficiency virus ( HIV ) type 1/2 immunodeficiency disease . Participant receive live vaccine within 4 week prior screen Known hypersensitivity component recombinant protein production Chinese Hamster Ovary ( CHO ) cell Participant expose investigational product ( IP ) investigational device another clinical study within 4 week prior IP administration , schedule participate another clinical study involve IP investigational device course study Participant nursing intend begin nurse course study Any disorder disease , clinically significant abnormality laboratory clinical test ( ) , medical judgment may impede participant 's participation study , pose increase risk participant , confound result study Participant family member employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>